The hardware and bandwidth for this mirror is donated by dogado GmbH, the Webhosting and Full Service-Cloud Provider. Check out our Wordpress Tutorial.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]dogado.de.

gsMAMS: Group Sequential Designs of Multi-Arm Multi-Stage Trials

It provides functions to generate operating characteristics and to calculate Sequential Conditional Probability Ratio Tests(SCPRT) efficacy and futility boundary values along with sample/event size of Multi-Arm Multi-Stage(MAMS) trials for different outcomes. The package is based on Jianrong Wu, Yimei Li, Liang Zhu (2023) <doi:10.1002/sim.9682>, Jianrong Wu, Yimei Li (2023) "Group Sequential Multi-Arm Multi-Stage Survival Trial Design with Treatment Selection"(Manuscript accepted for publication) and Jianrong Wu, Yimei Li, Shengping Yang (2023) "Group Sequential Multi-Arm Multi-Stage Trial Design with Ordinal Endpoints"(In preparation).

Version: 0.7.2
Imports: mvtnorm, stats, survival
Suggests: knitr, rmarkdown, testthat (≥ 3.0.0)
Published: 2024-05-10
DOI: 10.32614/CRAN.package.gsMAMS
Author: Tushar Patni [aut, cre], Yimei Li [aut], Jianrong Wu [aut]
Maintainer: Tushar Patni <tushar.patni006 at gmail.com>
BugReports: https://github.com/Tpatni719/gsMAMS/issues
License: GPL-3
URL: https://github.com/Tpatni719/gsMAMS
NeedsCompilation: no
Materials: NEWS
CRAN checks: gsMAMS results

Documentation:

Reference manual: gsMAMS.pdf
Vignettes: gsMAMS

Downloads:

Package source: gsMAMS_0.7.2.tar.gz
Windows binaries: r-devel: gsMAMS_0.7.2.zip, r-release: gsMAMS_0.7.2.zip, r-oldrel: gsMAMS_0.7.2.zip
macOS binaries: r-release (arm64): gsMAMS_0.7.2.tgz, r-oldrel (arm64): gsMAMS_0.7.2.tgz, r-release (x86_64): gsMAMS_0.7.2.tgz, r-oldrel (x86_64): gsMAMS_0.7.2.tgz
Old sources: gsMAMS archive

Linking:

Please use the canonical form https://CRAN.R-project.org/package=gsMAMS to link to this page.

These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.
Health stats visible at Monitor.